Elizabeth Pando Rau

One day highlights in #Pancreatic cancer Barcelona 4th Oct-Save the date! @MacarullaTeresa @VHIO @VHIR_ @vallhebron @JHernando3 @HelenaVeM

New @iScience_CP paper by @NinaSteele17 @Pasca_Lab Primary and metastatic cellular landscapes in human #PancreaticCancer cell.com/iscience/fullt… Signatures of pancreatic cancer metastases associated T cells (exhausted), macrophages (complement pathway) and fibroblasts (UPP1 +).

🔬Epithelial–mesenchymal transition (EMT) and cancer: what clinicians should know @NatRevClinOncol ✅Excellent review ✅Mechanism, clinical evidence, biomarkers, treatment strategies, ongoing trials, challenges 👉nature.com/articles/s4157… #cancer #oncology #MedX @OncoAlert

🇨🇳 #Innovent Biologics has registered a Phase III clinical trial for its novel Claudin18.2-targeting ADC drug, #IBI343, for the treatment of pancreatic cancer clinicaltrials.gov/study/NCT07066…. The trial, titled G-HOPE-002, plans to enroll 201 patients with advanced pancreatic cancer.…

♥️

Dr. Eileen O’Reilly (@EileenMOReilly) on the Rapidly Evolving Role of Local Therapy in Metastatic Pancreatic Cancer onclive.com/view/dr-o-reil… via @OncLive

Fantastic review of somatic testing in PDAC by @EileenMOReilly . Which are the validated biomarkers? How to test?Where we are today, where we need to be in the future…

Great overview of #PrecisionMedicine in #PDAC by @EileenMOReilly at @myESMO #ESMOGI25 If you missed it, please watch it 📺 🧬NGS important, with RNA for fusions 🫶KRAS 🤞🏻MTAP 👀Claudin 18.2 🤝Molecular Tumor Board-ESMO recomendations available #ESMOAmbassadors @BenWestphalen

Cindy Neuzillet in the Education Session: metastatic PDAC disease: treatment strategy in 2025 in 4 different tracks, including BSC. #ESMO25, #ESMOAmbassadors, @myESMO

📢 Join us for the 2nd #VHIOBBVASymposium on Cell-Based Therapies in Oncology ‼️ 🎯 Designed for scientists, researchers, clinicians, patient representatives, and students. 📍 @santpaubcn 🗓️ November 13-14, 2025 ℹ️ linke.to/2VHIOBBVASympo…

Just published in BMJ-SIT @bmj_latest !!💡 Brightening the path to safe liver transplants: the role of ICG fluorescence in biliary anastomosis. Another great use of ICG to make Liver Transplantation even safer. Thanks to the whole @vallhebron team!! sit.bmj.com/content/bmjsit…

The 2025 ASCO meeting featured research on pancreatic cancer, including a new treatment modality and a novel treatment combination. bit.ly/43VHWOL

🗨️ “Vaccines have done more to improve public health than any other medical intervention.” A new Viewpoint focuses on cancer vaccines and the future of immunotherapy—analysing trials, different vaccine approaches, and how the next generation of cancer vaccines can help improve…

Can select mPDAC be treated more aggressively? 🧬📉✂️ Our review, now published in The Oncologist, explores oligometastatic PDAC: biology, chemo, resection, SBRT, HIPEC, NIPEC & beyond. 🔗 academic.oup.com/oncolo/article… @chiaro_del @CUpancreas @CUDeptSurg @CUCancerCenter

94% Survival Rate: Phase 2a Trial Shows Breakthrough in Pancreatic Cancer Treatment stocktitan.net/news/IMRX/immu…

More evidence on small IPMN cysts, when no WF or HRS, similar risk for PDAC than the general population. Results From the PACIFIC Trial -⁦@ILevink⁩ onlinelibrary.wiley.com/doi/10.1002/ue…

⚠️Risk factors for pancreatic cancer @eClinicalMed ➡️Umbrella review 🚨New risk factors: ✔️autoimmune liver disease ✔️BRCA gene mutation ✔️co-infection with hepatitis B and C ✔️insulin use 👉thelancet.com/journals/eclin… @OncoAlert #cancer #oncology #MedX

📢 New study in @JHepatology led by @Florian_Castet & @MacarullaTeresa: PFS stands as the best current surrogate for OS in advanced biliary tract cancer. However, results stress the urgent need to develop novel endpoints in clinical trials for these patients. ➡️…

Proud of our PhD students for presenting their thesis projects on pancreatic surgery at Dublin #eahpba25 @EAHPBA —reflecting the steady progress at @vallhebron towards expanding radical surgical options for our pancreatic cancer patients @VHIO @VHIR_ @UABBarcelona